康希诺生物(06185)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06185 康希诺生物

已收盘 07-20 16:08:22

24.040

+0.840

+3.62%

最高24.200	最低23.200	成交量57.49万
今开23.200	昨收23.200	日振幅4.31%
总市值59.39亿	流通市值31.89亿	总股本2.47亿
成交额1,374万	换手率0.43%	流通股本1.33亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06185","market":"HK","secType":"STK","nameCN":"康希诺生物","latestPrice":24.04,"timestamp":1784534902005,"preClose":23.2,"halted":0,"volume":574867,"delay":0,"changeRate":0.036206896551724134,"floatShares":132670900,"shares":247043801,"eps":0.11,"marketStatus":"已收盘","change":0.84,"latestTime":"07-20 16:08:22","open":23.2,"high":24.2,"low":23.2,"amount":13743889,"amplitude":0.043103,"askPrice":24.06,"askSize":1800,"bidPrice":24.04,"bidSize":1600,"shortable":3,"etf":0,"ttmEps":-0.005,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784597400000},"marketStatusCode":5,"adr":0,"listingDate":1553702400000,"exchange":"SEHK","adjPreClose":23.2,"openAndCloseTimeList":[[1784511000000,1784520000000],[1784523600000,1784534400000]],"volumeRatio":0.762398,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688185","market":"SH","secType":"STK","nameCN":"康希诺","latestPrice":49.66,"timestamp":1784530800000,"preClose":49.55,"halted":0,"volume":2123800,"delay":0,"premium":"-58.20"}},"requestUrl":"/m/hq/s/06185","defaultTab":"news","newsList":[{"id":"2652259021","title":"康希诺生物(06185)：曼海欣®药品补充申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2652259021","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652259021?lang=zh_cn&edition=full","pubTime":"2026-07-19 18:13","pubTimestamp":1784455999,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康希诺生物 发布公告，本公司已获得中国国家药品监督管理局出具的《受理通知书》，根据该通知书，国家药监局已受理将本公司的ACYW135群脑膜炎球菌多糖结合疫苗的适用人群年龄范围由3月龄到6周岁儿童扩大至3月龄到17周岁人群的补充申请。曼海欣凭借其创新优势，展现出强劲的市场表现力，实现了市场占有率的不断攀升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469430.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1574","06185","BK1191","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167988872","title":"康希诺生物（06185）曼海欣适用人群扩龄补充申请获NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1167988872","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167988872?lang=zh_cn&edition=full","pubTime":"2026-07-19 18:10","pubTimestamp":1784455857,"startTime":"0","endTime":"0","summary":"2026年7月19日，康希诺生物股份公司发布自愿公告称，公司已收到中国国家药品监督管理局出具的《受理通知书》，国家药监局正式受理其关于将ACYW135群脑膜炎球菌多糖结合疫苗适用人群年龄范围由“3月龄到6周岁儿童”扩大至“3月龄到17周岁人群”的补充申请。曼海欣为我国首个脑膜炎球菌四价结合疫苗，2021年12月获批上市，并于2026年2月将适用人群年龄范围扩展至“3月龄到6周岁儿童”。公司提醒投资者在买卖公司股份时保持审慎。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651991128","title":"【券商聚焦】中信证券：新基药目录有望加速创新药基层落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2651991128","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651991128?lang=zh_cn&edition=full","pubTime":"2026-07-14 08:57","pubTimestamp":1783990650,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，《2026年版国家基本药物目录》于7月9日正式发布，将于9月1日起实施。该机构认为，本次新版基药目录新增药物均已属于医保药品，随着基药与医保的深度协同联动，有望极大加速创新药的基层落地，医保控费与创新回报形成良性循环。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985769","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600030","BK1161","LU1328277881.USD","LU0572944931.SGD","LU0405327494.USD","LU2476274720.SGD","HK0000165453.HKD","LU0043850808.USD","LU1961090484.USD","06160","06185","LU0051755006.USD","BK1610","01093","LU0314109678.HKD","LU0359201612.USD","LU0823426480.USD","LU0979878070.USD","LU2039709279.SGD","01177","IBBQ","09995","KURE","LU1226288253.USD","06978","LU1997244956.HKD","LU1226287792.SGD","02616","09688","06030","IE00BPRC5H50.USD","09926","MEDX","02142","02269","LU1960683339.HKD","SG9999002463.SGD","IE0008368742.USD","LU0327786744.USD","KCE","LU2328871848.SGD","LU2488822045.USD","LU0588546209.SGD","BK1500","LU1152091168.USD","LU0417516902.SGD","01801","159992","LU1242518931.SGD","01877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651568164","title":"【券商聚焦】中信建投：创新药企仍是高增长主线、BD交易持续催化业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2651568164","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651568164?lang=zh_cn&edition=full","pubTime":"2026-07-13 08:53","pubTimestamp":1783903985,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指出，1）制药产业链：创新药企仍是高增长主线，BD交易持续催化业绩。BD授权收入成为多家公司中期业绩关键变量。上游供应链受益于国产替代及下游需求恢复，Q2增速普遍提升，利润端弹性显著。建议关注Q2高增长公司的配置机会。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985645","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0008369823.USD","06160","LU1961090484.USD","BK1161","02269","IE00B0JY6N72.USD","KCE","LU0359202008.SGD","LU1688375341.USD","LU0051755006.USD","LU0455707207.USD","LU1813983027.USD","02616","06978","IBBQ","06185","09688","09926","LU1969619763.USD","BK1515","LU0516422366.SGD","LU2242644610.SGD","LU0348735423.USD","01093","LU1807302812.USD","01801","601066","LU0348825331.USD","MEDX","LU1226288170.HKD","01177","LU0348784397.USD","BD","LU0501845795.SGD","01877","LU2097828474.EUR","BK1588","IE00B5MMRT66.SGD","LU1960683339.HKD","LU0359201612.USD","LU2488822045.USD","KURE","LU0067412154.USD","159992","LU1993786604.SGD","02142","LU2097828631.EUR","09995","LU0456846285.SGD","IE0008368742.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174778295","title":"康希诺生物更新6月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1174778295","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174778295?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:33","pubTimestamp":1783067604,"startTime":"0","endTime":"0","summary":"2026年7月3日，康希诺生物股份公司发布2026年6月股份变动月报表。公告显示，截至2026年6月30日，公司法定/注册股本总额为人民币247,043,801元，较上月无变化，股本整体保持稳定。根据月报，康希诺生物的H股及A股在本报告期内未发生数量变动。H股于本月底保持132,670,900股，A股则维持114,372,901股，均未新增发行、购回或注销。本次公告由联席公司秘书崔进签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648634520","title":"【券商聚焦】中信建投：看好相关创新药及制药企业医保准入与商保增量空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2648634520","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648634520?lang=zh_cn&edition=full","pubTime":"2026-07-03 08:36","pubTimestamp":1783038993,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投研究指，2026年6月29日，国家医保局公示通过2026年基本医保目录及商保创新药目录调整初步形式审查的药品名单及相关信息。叠加今年首次引入的“预申报”机制，本次结果充分体现了医保目录调整对创新药的持续倾斜，看好相关创新药及制药企业的医保准入与商保增量空间。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985028","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1242518931.SGD","06978","LU0043850808.USD","01093","LU0315179316.USD","LU0417516738.SGD","06185","LU1226287875.USD","LU0501845795.SGD","LU0456846285.SGD","LU0979878070.USD","LU2039709279.SGD","LU2097828631.EUR","IE00B031HY20.USD","01477","01801","IE0008369823.USD","02616","LU0348766576.USD","LU0856984785.SGD","09688","LU1688375341.USD","LU0502904849.HKD","LU2488822045.USD","SG9999004220.SGD","159992","LU0072913022.USD","LU0516422366.SGD","LU1226287792.SGD","LU2476274720.SGD","09995","01877","LU1961090484.USD","01177","LU2778985437.USD","BK1589","LU2097828805.USD","LU0417516902.SGD","LU1969619763.USD","LU0067412154.USD","HK0000165453.HKD","09926","LU2097828714.EUR","LU3063872942.SGD","LU2476274308.USD","02269","06160","02142","601066","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646871535","title":"康希诺生物四价流脑结合疫苗(MCV4)获阿根廷注册证书 国际化布局再获重要进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2646871535","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646871535?lang=zh_cn&edition=full","pubTime":"2026-06-25 18:17","pubTimestamp":1782382655,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1515","BK1161","159646","06185","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646875238","title":"康希诺生物(06185)：MCV4获得阿根廷注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2646875238","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646875238?lang=zh_cn&edition=full","pubTime":"2026-06-25 17:13","pubTimestamp":1782378827,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康希诺生物 发布公告，公司的ACYW135群脑膜炎球菌多糖结合疫苗已获得阿根廷国家药品、食品和医疗器械管理局授予的注册证书。曼海欣7至59岁扩龄临床研究已取得临床总结报告，正在开展补充申请相关准备。公司的MCV4此次于阿根廷获得注册证书，是该产品国际化战略取得的重要成果，有利于提升公司的国际认可度。MCV4于阿根廷实现销售的具体时间和销售金额目前尚存在一定的不确定性，后续需根据已获批适用人群的市场需求而定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458705.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康希诺生物(06185)：MCV4获得阿根廷注册证书","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06185","BK1515","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646840322","title":"【券商聚焦】中信证券：中国创新药BD交易金额超预期增长 即将进入密集数据催化期","url":"https://stock-news.laohu8.com/highlight/detail?id=2646840322","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646840322?lang=zh_cn&edition=full","pubTime":"2026-06-25 09:03","pubTimestamp":1782349398,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研报指，2026年以来，中国创新药BD交易金额超预期增长，产业全球竞争力进一步提升；国内市场快速放量，从2025年报来看，头部创新药企业在新产品驱动下，创新药收入快速增长，Biopharma陆续进入盈利拐点。研报认为创新药产业全球价值凸显，接下来将进入密集数据催化期。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984448","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B0JY6N72.USD","LU0540923850.HKD","09688","IE00B5MMRT66.SGD","IE0008368742.USD","LU0359202008.SGD","09995","LU1328277881.USD","LU1997245094.SGD","LU1813983027.USD","06030","BK0028","06160","LU0823426480.USD","LU0327786744.USD","SG9999002562.SGD","LU1794554557.SGD","LU2289578879.USD","02269","BK0196","LU2328871848.SGD","LU2039709279.SGD","IE00B031HY20.USD","01093","06185","SG9999004220.SGD","159992","01177","BD","LU0501845795.SGD","02142","LU1960683339.HKD","02616","BK1610","LU0181495838.USD","LU1226288253.USD","06978","SG9999002463.SGD","09926","01877","LU2097828474.EUR","LU0405327148.USD","IE00BZ08YT58.USD","BK1574","LU1064130708.USD","01801","LU1242518857.USD","600030","LU0856984785.SGD","LU0348767384.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128859307","title":"康希诺生物更新2026年5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1128859307","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128859307?lang=zh_cn&edition=full","pubTime":"2026-06-02 16:43","pubTimestamp":1780389792,"startTime":"0","endTime":"0","summary":"康希诺生物于2026年6月2日披露其截至2026年5月31日的股份变动月报表。报告显示，公司本月已发行股份总数和各类注册股本均无增减变动，股本结构保持稳定。根据公告，康希诺生物截至2026年5月31日的注册股本合计为人民币247,043,801元。另据公告，此次报告期内公司整体股本数保持不变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638565453","title":"康希诺生物(06185)：PCV24启动I/II期临床试验并完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2638565453","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638565453?lang=zh_cn&edition=full","pubTime":"2026-05-26 08:23","pubTimestamp":1779755014,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康希诺生物 发布公告，本公司开发的24价肺炎球菌多糖结合疫苗于近日正式启动I/II期临床试验，并完成首例受试者入组。本公司开发的PCV24于2026年1月获得中国国家药品监督管理局的临床试验批准。PCV24是本公司肺炎产品组合的进一步产品布局，截至本公告披露日，24价肺炎球菌多糖结合疫苗在国内外均无上市产品。I/II期临床试验为评价PCV24在2月龄及以上人群中接种的安全性与免疫原性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445778.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","06185","BK1191","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188118330","title":"康希诺生物拟回购不超已发行股本10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1188118330","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188118330?lang=zh_cn&edition=full","pubTime":"2026-05-19 16:46","pubTimestamp":1779180402,"startTime":"0","endTime":"0","summary":"康希诺生物日前发布公告，公司董事会决议将提请股东大会审议并授权其在合法合规的情况下，回购不超过满足授权决议当日已发行股份总数10%的A股及/或H股。若获股东大会通过，回购将以公司自有资金执行，并在遵守适用法律法规及上市规则的前提下进行，资金来源合法合规。董事会强调，本次回购不会在损害公司持续经营能力或影响其正常业务发展的情况下进行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康希诺生物拟回购不超已发行股本10%股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636030884","title":"【券商聚焦】招银国际：AI有望改变创新药研发范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2636030884","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636030884?lang=zh_cn&edition=full","pubTime":"2026-05-19 13:13","pubTimestamp":1779167581,"startTime":"0","endTime":"0","summary":"当前，监管框架持续完善，传统药企与AI原生公司加速合作，AI制药正处于从研发提效工具迈向创新药研发范式重构的转折期。AI重构药物研发全链条，早期效率红利已率先显现。传统创新药研发长期受困于高成本、长周期和低成功率，AI技术正在改变靶点发现、分子筛选与优化等关键环节的研发范式。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981743","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHAT","02616","AIPO","LU0326950275.SGD","09688","LU0072913022.USD","01877","06160","AGIX","09995","LU0348767384.USD","IE00BPRC5H50.USD","LU1226287792.SGD","LU1303224171.USD","LU0856984785.SGD","LU1880383366.USD","BK1588","LU0572944931.SGD","LU0140636845.USD","LU0456827905.SGD","02142","02269","159992","LU2097828631.EUR","LU1152091168.USD","09926","LU0315179316.USD","LU0516422952.EUR","06185","ARTY","LU0634319403.HKD","BK1583","IE00B031HY20.USD","BK1589","LU1960683339.HKD","LU1226288170.HKD","06978","01093","LU0067412154.USD","LU0561508036.HKD","LU1993786604.SGD","LU0348827113.USD","LU0456846285.SGD","01177","SG9999002562.SGD","LU0417516738.SGD","LU1719994722.HKD","BK1161","LU1152091754.HKD","01801"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2636483820","title":"【券商聚焦】中信建投：创新药迎盈利兑现期 国内商业化与海外授权双轮驱动业绩增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2636483820","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636483820?lang=zh_cn&edition=full","pubTime":"2026-05-18 09:32","pubTimestamp":1779067963,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年上半年医药行业触底回暖，创新药迎来盈利兑现期，国内商业化与海外授权双轮驱动业绩增长，多家企业扭亏。26Q1对外授权总额超600亿美元，ADC、双抗等前沿赛道交易持续火热。2026年ASCO年会94项中国研究中选口头报告，依沃西单抗登上全体大会，标志着中国创新药全球学术影响力迈上新台阶。国内支付端医保谈判与商保目录合力支持真创新。建议关注创新药国际化、边际改善等结构性机会。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981512","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","BK1161","LU1152091168.USD","LU0359202008.SGD","IE00BZ08YS42.EUR","LU2097828557.USD","LU1303224171.USD","LU1242518857.USD","BK1141","IE00B543WZ88.USD","LU1688375341.USD","09688","BK1574","LU0348827113.USD","LU2399975544.HKD","06978","LU0039217434.USD","LU0588546209.SGD","LU2097828631.EUR","SG9999002562.SGD","02616","02269","06185","06160","159992","LU1226287875.USD","LU1152091754.HKD","LU0979878070.USD","09995","LU0456827905.SGD","02142","IE00B5MMRT66.SGD","01093","601066","IE00B0JY6N72.USD","IE00BZ08YR35.GBP","LU0417516738.SGD","LU0561508036.HKD","01877","IE00BZ08YT58.USD","LU0516423174.USD","LU1242518931.SGD","LU1993786604.SGD","LU1969619763.USD","09926","LU2097828474.EUR","LU0516422952.EUR","LU0326950275.SGD","01801","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634016296","title":"智通AH统计|5月12日","url":"https://stock-news.laohu8.com/highlight/detail?id=2634016296","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634016296?lang=zh_cn&edition=full","pubTime":"2026-05-12 16:27","pubTimestamp":1778574421,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止5月12日收盘，东北电气、浙江世宝、中石化油服分列AH溢价率前三位，溢价率分别为513.64%、344.81%、302.60%；宁德时代、兆易创新、药明康德分列AH溢价率末三位，溢价率分别为-19.99%、-16.60%、-4.65%。其中大唐发电、晨鸣纸业、南华期货股份的偏离值位居前三，分别为59.58%、36.27%、34.90%；另外，东北电气、长飞光纤光缆、中芯国际的偏离值位居后三，分别为-53.05%、-21.38%、-20.29%。　　前十大AH股溢价率排行。　　股票名称H股(港元)A股溢价率↓偏离值","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260512/32217919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02899","00588","00991","01800","03986","03328","00568","688981","02238","03145","82318","01276","02628","03908","399300","159982","EWH","06869","03968","02338","HPAD.SI","02359","01057","06196","03143","01766","02701","601318","03750","01108","00386","00042","PNGAY","06680","00187","02691","01812","00981","00300","03996","01033","01349","00553","02465","03678","02318","06185","PAImain","02218"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634140182","title":"康希诺生物(06185)：青少年及成人用Td5cp的NDA获国家药监局药品审评中心纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2634140182","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634140182?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:48","pubTimestamp":1778489303,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康希诺生物 发布公告，公司为其吸附无细胞百(五组分)白破联合疫苗的新药上市申请获得中国国家药品监督管理局药品审评中心纳入优先审评。根据国家优先审评审批的规定，国家药监局药品审评中心对纳入优先审评审批的NDA，将优先配置资源进行审评。青少年及成人用Td5cp适用于6岁及以上人群，为青少年及成人的百白破加强疫苗。公司正在准备青少年及成人用Td5cp的NDA递交工作","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440186.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康希诺生物(06185)：青少年及成人用Td5cp的NDA获国家药监局药品审评中心纳入优先审评","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1515","BK1191","BK1161","06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135659717","title":"康希诺生物4月股份变动月报表出炉，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1135659717","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135659717?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:52","pubTimestamp":1778057574,"startTime":"0","endTime":"0","summary":"康希诺生物股份公司于2026年5月6日发布2026年4月股份变动月报表。公告显示，截至2026年4月30日，公司已发行股份总数与上月保持一致，股本结构整体未发生变化。根据月报披露，康希诺生物现有普通股股本分为H股和A股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631858486","title":"瑞银：降康希诺生物(06185)目标价至52.4港元 首季业绩符预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2631858486","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631858486?lang=zh_cn&edition=full","pubTime":"2026-04-30 15:55","pubTimestamp":1777535726,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，康希诺生物(06185)今年首季业绩符合预期。期内，收入为1.9亿元人民币(下同)，同比增长38.7%，略高于该行预测2026年全年34%的增长; 净亏损为4,000万元，对比该行预测今年全年盈利3.37亿元。瑞银调整集团2026年至2028年每股盈利预测，由原先的1.36元、2.26元及3.77元分别下调至0.77元、2.15元及3.58元。目标价由59.8港元下调至52.4港元;评级“买入”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437171.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194176889","title":"异动解读 | 首季净亏损同比扩大250%，康希诺生物盘中大跌5.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=1194176889","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194176889?lang=zh_cn&edition=full","pubTime":"2026-04-29 11:01","pubTimestamp":1777431664,"startTime":"0","endTime":"0","summary":"康希诺生物今日盘中股价大幅下挫，跌幅达5.87%，引起了市场的广泛关注。消息面上，公司发布了第一季度财务报告，业绩表现不佳是导致股价承压的主要原因。报告显示，公司归属于上市公司股东的净亏损为4042.43万元人民币，与去年同期相比，亏损幅度惊人地扩大了250.13%。尽管期内营业收入实现了38.73%的同比增长，达到1.9亿元，但巨额的亏损扩大以及经营活动产生的现金流量净额为净流出6702.16万元，加剧了投资者对公司盈利能力和现金流状况的担忧，从而引发了抛售。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170599465","title":"康希诺生物2026年第一季度财报营收1.90亿元，经调整净利润-5511.52万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1170599465","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170599465?lang=zh_cn&edition=full","pubTime":"2026-04-28 17:03","pubTimestamp":1777367026,"startTime":"0","endTime":"0","summary":"根据康希诺生物发布的2026年第一季度报告，报告期内，公司实现营业收入1.90亿元人民币，较上年同期增长38.73%。其中，四价流脑结合疫苗“曼海欣”保持较高销量，13价肺炎球菌多糖结合疫苗“优佩欣”成功上市后也贡献了可观收入，国际技术转移及中间品销售业务则成为新的收入增长点。经调整净利润方面，本期归属于上市公司股东的扣除非经常性损益后的净亏损为-5511.52万元。研发投入合计7669.96万元，占营业收入比例为40.31%，同比下降24.52个百分点。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"康希诺生物2026年第一季度财报营收1.90亿元，经调整净利润-5511.52万元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06185"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cansinotech.com","stockEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":0.0376},{"period":"3month","weight":-0.3409},{"period":"6month","weight":-0.3793},{"period":"1year","weight":-0.4074},{"period":"ytd","weight":-0.3356}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0103},{"period":"3month","weight":-0.0611},{"period":"6month","weight":-0.085},{"period":"1year","weight":0.0026},{"period":"ytd","weight":-0.0417}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康希诺生物股份公司是一家处于临床阶段的中国疫苗公司。该公司的产品包括埃博拉病毒疫苗Ad5-EBOV、脑膜炎球菌疫苗MCV2和MCV4、肺炎球菌疫苗PBPV和重组新型冠状病毒疫苗等。其产品主要应用于脑膜炎、百白破和肺炎领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.030578},{"month":2,"riseRate":0.857143,"avgChangeRate":0.172684},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.060436},{"month":4,"riseRate":0.625,"avgChangeRate":0.049828},{"month":5,"riseRate":0.25,"avgChangeRate":-0.051769},{"month":6,"riseRate":0.5,"avgChangeRate":0.015607},{"month":7,"riseRate":0.625,"avgChangeRate":0.054348},{"month":8,"riseRate":0.142857,"avgChangeRate":-0.143307},{"month":9,"riseRate":0.714286,"avgChangeRate":0.068326},{"month":10,"riseRate":0.428571,"avgChangeRate":0.059174},{"month":11,"riseRate":0.571429,"avgChangeRate":0.088604},{"month":12,"riseRate":0.571429,"avgChangeRate":-0.035813}],"exchange":"SEHK","name":"康希诺生物","nameEN":"CANSINOBIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康希诺生物(06185)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康希诺生物(06185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康希诺生物,06185,康希诺生物股票,康希诺生物股票老虎,康希诺生物股票老虎国际,康希诺生物行情,康希诺生物股票行情,康希诺生物股价,康希诺生物股市,康希诺生物股票价格,康希诺生物股票交易,康希诺生物股票购买,康希诺生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康希诺生物(06185)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康希诺生物(06185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}